ABSTRACT
Short-rib thoracic dystrophies (SRTDs) are congenital disorders due to defects in primary cilium function. SRTDs are recessively inherited with mutations identified in 14 genes to date (comprising 398 exons). Conventional mutation detection (usually by iterative Sanger sequencing) is inefficient and expensive, and often not undertaken. Whole exome massive parallel sequencing has been used to identify new genes for SRTD (WDR34, WDR60 and IFT172); however, the clinical utility of whole exome sequencing (WES) has not been established. WES was performed in 11 individuals with SRTDs. Compound heterozygous or homozygous mutations were identified in six confirmed SRTD genes in 10 individuals (IFT172, DYNC2H1, TTC21B, WDR60, WDR34 and NEK1), giving overall sensitivity of 90.9%. WES data from 993 unaffected individuals sequenced using similar technology showed two individuals with rare (minor allele frequency <0.005) compound heterozygous variants of unknown significance in SRTD genes (specificity >99%). Costs for consumables, laboratory processing and bioinformatic analysis were Subject(s)
Abnormalities, Multiple/genetics
, Exome/genetics
, Genetic Predisposition to Disease/genetics
, Mutation
, Ribs/abnormalities
, Sequence Analysis, DNA/methods
, Thorax/pathology
, Abnormalities, Multiple/diagnosis
, Adaptor Proteins, Signal Transducing/genetics
, Adult
, Carrier Proteins/genetics
, Cell Cycle Proteins/genetics
, Child
, Child, Preschool
, Cytoplasmic Dyneins/genetics
, Cytoskeletal Proteins
, Genotype
, Humans
, Infant, Newborn
, Microtubule-Associated Proteins/genetics
, NIMA-Related Kinase 1
, Protein Serine-Threonine Kinases/genetics
, Reproducibility of Results
, Sensitivity and Specificity
ABSTRACT
After genotoxic stress, normal cells trigger DNA repair or, if unable to repair, undergo apoptosis to eradicate the cells that bear the risk of becoming tumorigenic. Here we show that repression of the transcription factor, activating transcription factor 3 (ATF3), after ultraviolet (UV)-mediated genotoxic stress impairs the DNA repair process. We provide evidence that ATF3 directly regulates the proliferating cell nuclear antigen (PCNA)-associated factor KIAA0101/p15(PAF). We further show that the expressions of ATF3 and p15(PAF) is sufficient to trigger the DNA repair machinery, and that attenuation of their expression alters DNA repair mechanisms. We show that the expression of p15(PAF) compensates for a lack of ATF3 expression, thereby constituting a major effector of ATF3 in the DNA repair process. In addition, we provide evidence that p15(PAF) expression is required for the correct function of PCNA during DNA repair, as prevention of their interaction significantly alters DNA repair mechanisms. Finally, defective DNA repair, because of the downregulation of p15(PAF) expression, rendered the cells more sensitive to UV-induced cell death. Therefore, our results suggest ATF3 and p15(PAF) as novel gatekeepers of genomic integrity after UV exposure.
Subject(s)
Activating Transcription Factor 3/metabolism , Carrier Proteins/metabolism , DNA Repair , Apoptosis , Cell Line , DNA Damage , DNA-Binding Proteins , Down-Regulation , Genome , HeLa Cells , Humans , Proliferating Cell Nuclear Antigen/metabolism , RNA, Small Interfering/metabolism , RNA, Small Interfering/pharmacology , Ultraviolet RaysABSTRACT
Nevoid Basal Cell Carcinoma Syndrome (NBCCS) is an autosomal dominant disorder characterised by multiple basal cell carcinomas, palmar and plantar pitting, odontogenic keratocysts of the jaws and bilamellar calcification of the falx. Mutations in the PTCH gene are responsible for NBCCS but most studies have found mutations in less than half of the cases tested. We used denaturing high performance liquid chromatography (DHPLC) to screen for PTCH mutations in 28 NBCCS cases, most of whom had been previously evaluated by single stranded conformation polymorphism analysis but found to be negative. Protein truncating (n = 10) and missense or indel (n = 4) mutations were found in 14/28 (50%) cases and one additional case carried an unclassified variant, c.2777G>C. Thirteen of the variants were novel. The mutation frequency was similar in inherited and de novo cases. Three of the missense and indel mutations were in the sterol-sensing domain, and one was in the sixth transmembrane domain.
Subject(s)
Basal Cell Nevus Syndrome/genetics , Chromatography, High Pressure Liquid/methods , DNA Mutational Analysis/methods , Mutation, Missense , Receptors, Cell Surface/genetics , Skin Neoplasms/genetics , Sterols/chemistry , Female , Genes, Dominant , Heterozygote , Humans , Male , Patched Receptors , Patched-1 Receptor , Protein Structure, TertiarySubject(s)
Mutation , Oxidoreductases Acting on CH-CH Group Donors , Oxidoreductases/genetics , Smith-Lemli-Opitz Syndrome/enzymology , Australia , Cells, Cultured , Female , Fetus , Fibroblasts/physiology , Humans , Infant , Infant, Newborn , Oxidoreductases/blood , Pregnancy , Reverse Transcriptase Polymerase Chain Reaction , Skin/metabolism , Smith-Lemli-Opitz Syndrome/geneticsABSTRACT
It has long been known from work in both Drosophila and vertebrate systems that the hedgehog signalling pathway is pivotal to embryonic development, but the past 5 years has seen an increase in our understanding of how members of this pathway are crucial to the processes of tumorigenesis. This important link was firmly established with the discovery that mutations in the gene encoding the hedgehog receptor molecule patched are responsible for both familial and sporadic forms of basal cell carcinoma (BCC), as well as a number of other tumour types. It is now known that a number of key members of the hedgehog cascade are involved in tumorigenesis, and dysregulation of this pathway appears to be a key element in the aetiology of a range of tumours.
Subject(s)
Carcinoma, Basal Cell/genetics , Signal Transduction , Skin Neoplasms/genetics , Trans-Activators/physiology , Animals , Carcinoma, Basal Cell/drug therapy , Hedgehog Proteins , Humans , Membrane Proteins/genetics , Models, Biological , Mutation , Neoplasms/drug therapy , Neoplasms/genetics , Patched Receptors , Receptors, Cell Surface , Skin Neoplasms/drug therapyABSTRACT
Inactivating mutations in the human patched (PTCH) gene have been identified in both familial and sporadic basal cell carcinomas (BCCs). In some tumors mutations have been detected in both alleles thereby supporting the role of PTCH as a tumor suppressor gene. We have analyzed 22/23 coding exons of PTCH for mutations in 44 sporadic BCCs, and detected 10 novel mutations in nine tumors. In two of the mutant tumors the remaining allele was inactivated by loss of heterozygosity. Five novel PTCH polymorphisms were also identified. Most of the variations found were C>T substitutions at dipyrimidine sites, supporting previous studies which indicate a role for ultraviolet-B in the genesis of sporadic BCCs.
Subject(s)
Carcinoma, Basal Cell/genetics , Membrane Proteins/genetics , Mutation , Skin Neoplasms/genetics , Alleles , Amino Acid Substitution/physiology , Arsenic Poisoning/pathology , Australia/epidemiology , Carcinoma, Basal Cell/ethnology , Carcinoma, Basal Cell/pathology , DNA Mutational Analysis , DNA Primers/chemistry , DNA, Neoplasm/genetics , Female , Genes, Tumor Suppressor , Humans , Loss of Heterozygosity , Male , Molecular Sequence Data , Patched Receptors , Patched-1 Receptor , Polymorphism, Genetic , Polymorphism, Single-Stranded Conformational , Receptors, Cell Surface , Skin Neoplasms/ethnology , Skin Neoplasms/pathologyABSTRACT
Loss of heterozygosity occurs frequently on the short arm of chromosome 8 in many neoplasms, including colorectal and ovarian cancer. Monochromosome transfer experiments into colorectal tumour cell lines have provided functional evidence for a tumour suppressor gene located at 8p22-23. One of the genes from this region that is expressed by our suppressed hybrids is a candidate tumour suppressor gene, DLC1 (deleted in liver cancer), which has homology to rat RhoGAP. We have delineated the structure of the DLC1 gene and used single-stranded conformation polymorphism analysis (SSCP) to look for sequence variants in 126 colorectal and 33 ovarian primary tumours and cell lines. One exonic missense mutation and three intronic insertions/deletions were identified in primary colorectal tumours, as well as many polymorphisms present in germline DNAs. The rarity of exonic missense mutations, and the absence of protein-truncating mutations, indicates that DLC1 is not the target of 8p LOH in colorectal or ovarian tumours. The delineation of the gene structure allows mutation analysis of DLC1 in other tumour types for which it remains a candidate tumour suppressor gene based on its location and homology to rhoGAP.
Subject(s)
Colorectal Neoplasms/genetics , Genes, Tumor Suppressor , Genetic Variation/genetics , Mutation/genetics , Ovarian Neoplasms/genetics , Proteins/genetics , Tumor Suppressor Proteins , 5' Untranslated Regions/genetics , Animals , Chromosomes, Human, Pair 8/genetics , Colorectal Neoplasms/pathology , Exons/genetics , Expressed Sequence Tags , Female , GTPase-Activating Proteins/chemistry , GTPase-Activating Proteins/genetics , Humans , Hybrid Cells , Introns/genetics , Loss of Heterozygosity/genetics , Ovarian Neoplasms/pathology , Polymorphism, Single-Stranded Conformational , RNA, Messenger/analysis , RNA, Messenger/genetics , Tumor Cells, CulturedABSTRACT
Mutations of the human Patched gene ( PTCH ) have been identified in individuals with the nevoid basal cell carcinoma syndrome (NBCCS) as well as in sporadic basal cell carcinomas and medulloblastomas. We have isolated a homologue of this tumour suppressor gene and localized it to the short arm of chromosome 1 (1p32.1-32.3). Patched 2 ( PTCH2 ) comprises 22 coding exons and spans approximately 15 kb of genomic DNA. The gene encodes a 1203 amino acid putative transmembrane protein which is highly homologous to the PTCH product. We have characterized the genomic structure of PTCH2 and have used single-stranded conformational polymorphism analysis to search for mutations in PTCH2 in NBCCS patients, basal cell carcinomas and in medulloblastomas. To date, we have identified one truncating mutation in a medulloblastoma and a change in a splice donor site in a basal cell carcinoma, suggesting that the gene plays a role in the development of some tumours.
Subject(s)
Carcinoma, Basal Cell/genetics , Chromosomes, Human, Pair 1/genetics , DNA, Neoplasm/isolation & purification , Genes, Tumor Suppressor/genetics , Medulloblastoma/genetics , Membrane Proteins/genetics , Amino Acid Sequence , Chromosome Mapping , DNA, Complementary/chemistry , DNA, Complementary/genetics , DNA, Neoplasm/chemistry , DNA, Neoplasm/genetics , Humans , Molecular Sequence Data , Mutation , Patched Receptors , Patched-1 Receptor , Patched-2 Receptor , Polymorphism, Single-Stranded Conformational , Receptors, Cell Surface , Sequence Homology, Amino AcidABSTRACT
The hedgehog signalling pathway is responsible for the embryonic patterning of a range of tissues, and it is now known that dysregulation of this pathway can result in the formation of several tumour types. This cascade is regulated at the cell surface by the opposing actions of the patched and smoothened molecules which together form a receptor complex for hedgehog. The discovery that inactivation of the human patched gene is responsible for familial and sporadic forms of basal cell carcinoma firmly established a role for dysregulation of hedgehog signalling in tumorigenesis. Other key members of this pathway have also been shown to be involved in tumour formation, as have more distal downstream targets of hedgehog signalling. Since it appears that tumorigenesis results from constitutive activation of hedgehog responsive genes, the identification of novel downstream targets of hedgehog signalling in given cell types is likely to increase our understanding of the molecular processes underlying tumour formation.
Subject(s)
Cell Transformation, Neoplastic , Drosophila Proteins , Embryonic Induction , Embryonic and Fetal Development , Proteins/metabolism , Signal Transduction/physiology , Trans-Activators , Animals , Basal Cell Nevus Syndrome/genetics , Drosophila , Hedgehog Proteins , Humans , Insect Proteins/chemistry , Insect Proteins/metabolism , Membrane Proteins/genetics , Membrane Proteins/metabolism , Patched Receptors , Proteins/genetics , Receptors, Cell SurfaceABSTRACT
The Cdx2 gene is one of three murine homologues of the Drosophila homeobox gene caudal. Mice heterozygous for a null mutation in Cdx2 exhibit a variable phenotype including tail abnormalities, stunted growth and a homeotic shift of vertebrae. Most strikingly, however, 90% of heterozygous mice were reported to develop multiple intestinal adenomatous polyps, most notably in the proximal colon (Chawengsaksophak et al., 1997). These observations led us to propose that mutation of CDX2 may be involved in the genesis of some human colorectal tumours. A survey of DNA from 85 colorectal tumours revealed that one with extensive microsatellite instability (RER+ phenotype) has mutations in both alleles of CDX2. Both mutations occur in coding regions which contain repetitive elements and are consistent with those found in RER + tumours.
Subject(s)
Adenocarcinoma/genetics , Alleles , Colorectal Neoplasms/genetics , Homeodomain Proteins/genetics , Mutation , Aged , Aged, 80 and over , Animals , CDX2 Transcription Factor , Drosophila , Drosophila Proteins , Female , Humans , Male , Mice , Polymorphism, Genetic , Polymorphism, Single-Stranded Conformational , Trans-Activators , Transcription FactorsABSTRACT
We have previously identified the human homologue of the Drosophila patched gene and have described, in this gene, mutations that give rise to naevoid basal cell carcinoma syndrome (NBCCS). Here, we have analysed the effects of three splice site mutations within human PATCHED (PTCH) by the reverse transcription/polymerase chain reaction method in cultured patient lymphocyte cell lines. Two alterations, a point mutation in intron 7 and an insertion in intron 10, lead to premature truncation of the PATCHED protein. Another point mutation in intron 17 results in the skipping of exon 18 and the subsequent in-frame deletion of 46 amino acids. Additionally, in all lymphocyte and keratinocyte cell lines examined, exon 10 of PTCH is alternatively spliced leading to an in-frame deletion of 52 amino acids.
Subject(s)
Basal Cell Nevus Syndrome/genetics , Membrane Proteins/genetics , Mutation , Alternative Splicing , Humans , Patched Receptors , Patched-1 Receptor , Receptors, Cell Surface , Tumor Cells, CulturedABSTRACT
The human homologue of the Drosophila segment polarity gene patched is mutated in the cancer predisposition syndrome naevoid basal cell carcinoma syndrome (NBCCS), as well as in several types of tumour associated with the disorder. It was recently reported that a single recurrent mutation in the SONIC HEDGEHOG gene, which encodes the PATCHED ligand, was found in one of 43 basal cell carcinomas (BCCs), one of 14 medulloblastomas and one of six breast carcinomas analysed (Oro et al., 1997). We have searched extensively for this same mutation in a large collection of BCCs, medulloblastomas and carcinomas of the breast, ovary and colorectum and have failed to detect the mutation in any sample analysed.
Subject(s)
Mutation , Neoplasms/genetics , Proteins/genetics , Trans-Activators , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Hedgehog Proteins , Humans , Infant , Male , Middle AgedABSTRACT
Mutations in the human patched gene have recently been detected in patients with naevoid basal cell carcinoma syndrome. We have characterised a further 5 novel germ line mutations in patients presenting with multiple odontogenic keratocysts. Four mutations cause premature stop codons and one mutation results in an amino-acid substitution towards the carboxyl terminus of the predicted patched protein. No obvious genotype-phenotype correlations could be interpreted, consistent with previous studies.
Subject(s)
Basal Cell Nevus Syndrome/genetics , Germ-Line Mutation/genetics , Membrane Proteins/genetics , Adolescent , Adult , Child , Codon, Terminator/genetics , DNA Mutational Analysis , Exons/genetics , Humans , Male , Patched Receptors , Polymorphism, Single-Stranded Conformational , Receptors, Cell SurfaceABSTRACT
Inactivating mutations in the PTCH gene, a human homologue of the Drosophila segment polarity gene patched, have been identified recently in patients with nevoid basal cell carcinoma syndrome. These patients are predisposed to various neoplasias including basal cell carcinomas and medulloblastomas (MBs). To determine the involvement of PTCH in sporadic MBs, which represent the most frequent malignant brain tumors in children, we screened for PTCH alterations in an unselected panel of 64 biopsy samples from 62 patients and four continuous MB cell lines, all derived from patients with sporadic MBs. Using single-strand conformational polymorphism analysis, we screened exons 2-22 and detected nonconservative PTCH mutations in 3 of 11 samples from sporadic cases of the desmoplastic variant of MB but none in 57 MBs with classical (nondesmoplastic) histology. In two of the tumors with mutations and in two additional desmoplastic cases, loss of heterozygosity was found at 9q22. These findings suggest that PTCH represents a tumor suppressor gene involved in the development of the desmoplastic variant of MB.
Subject(s)
Cerebellar Neoplasms/genetics , Medulloblastoma/genetics , Membrane Proteins/genetics , Adolescent , Animals , Child , Child, Preschool , Female , Gene Expression Regulation, Neoplastic , Genetic Variation , Humans , Infant , Male , Middle Aged , Mutation , Patched Receptors , Patched-1 Receptor , Polymorphism, Single-Stranded Conformational , RNA, Messenger/analysis , RNA, Messenger/metabolism , Receptors, Cell Surface , Sequence Analysis, DNA , Tumor Cells, CulturedABSTRACT
The human homologue of the Drosophila segment polarity gene patched is implicated in the development of nevoid basal cell carcinoma syndrome (NBCCS) and in the genesis of sporadic basal cell carcinomas. In order to examine the phenotypic variability in NBCCS and to highlight functionally important domains of the PTCH protein, we have now screened 71 unrelated NBCCS individuals for mutations in the PTCH exons. We identified 28 mutations that are distributed throughout the entire gene, and most (86%) cause protein truncation. As part of this analysis, we demonstrate that failure of one NBCCS family to show clear linkage to chromosome 9q22.3-31 is most likely due to germinal mosaicism. We have identified three families bearing identical mutations with variable phenotypes, suggesting phenotypic variability in NBCCS is a complex genetic event. No phenotype genotype correlation between the position of truncation mutations and major clinical features was evident. Two missense mutations have been identified, and their location within transmembrane domains supports the notion that PTCH may have a transport function. The preponderance of truncation mutants in the germ line of NBCCS patients suggests that the developmental defects associated with the disorder are most likely due to haploinsufficiency.
Subject(s)
Basal Cell Nevus Syndrome/genetics , Germ-Line Mutation , Membrane Proteins/genetics , Exons , Female , Genotype , Humans , Male , Molecular Sequence Data , Mosaicism , Patched Receptors , Patched-1 Receptor , Pedigree , Phenotype , Polymorphism, Single-Stranded Conformational , Receptors, Cell Surface , Transcription, GeneticABSTRACT
Chromosome 9q22 is a gene-rich region to which several human disease loci have been mapped. Pulsed field gel electrophoresis (PFGE) and FISH were used to determine the order of and distance between 12 chromosome 9q22 markers flanked by D9S196 and D9S180. D9S780 and XPA were within 190 kb of each other and hybridized to the same 460-kb NotI fragment as D9S180. ZNF169, a novel kruppel-type gene, and D9S280 shared several PFGE fragments indicating that they are not more than 300 kb apart. Interphase FISH showed that COL15A1 lies distal to the region bounded by D9S180 and D9S196 and that ZNF169 is adjacent to D9S196. Based on the restriction fragment lengths in this region and estimates from FISH, the distance from D9S180 to D9S196 is not less than 2 Mb.
Subject(s)
Basal Cell Nevus Syndrome/genetics , Chromosomes, Human, Pair 9 , Zinc Fingers/genetics , Carcinoma, Squamous Cell/genetics , Chromosome Mapping , Electrophoresis, Gel, Pulsed-Field , Genetic Markers , Humans , In Situ Hybridization, Fluorescence , Tumor Cells, CulturedABSTRACT
Many genes originally identified because of their role in embryonic development are also important in control of cell growth and differentiation postnatally. Mutations in some of these genes have been shown to contribute to carcinogenesis. The nevoid basal cell carcinoma syndrome is an autosomal dominant disorder that predisposes to basal cell carcinomas of the skin as well as widespread developmental defects. The gene for this disorder, NBCCS, maps to chromosome 9q22.3, and loss of heterozygosity at this site in both sporadic and hereditary basal cell carcinomas suggests that it functions as a tumor suppressor. NBCCS was positionally cloned and shown to be the human homologue of the Drosophila gene, patched. Drosophila patched is part of the hedgehog signaling pathway, important in determining embryonic patterning and cell fate in multiple structures of the developing embryo. That mutations in human patched result in dysregulation of several genes known to play a role in both organogenesis and carcinogenesis may explain both the birth defects and the cancer predisposition seen in the nevoid basal cell carcinoma syndrome.
Subject(s)
Basal Cell Nevus Syndrome/genetics , Animals , Cloning, Molecular , Drosophila , Gene Expression Regulation, Developmental , Genes, Tumor Suppressor/genetics , Humans , Insect Hormones/genetics , Membrane Proteins/genetics , Signal Transduction/genetics , Skin Neoplasms/geneticsABSTRACT
The demonstration that mutations in the Patched (PTCH) gene cause nevoid basal cell carcinoma syndrome (NBCCS) has led to the identification of the exact molecular lesion in a percentage of individuals with the syndrome. In addition, it has been possible to determine, through molecular analysis of parents and other relatives of these individuals, if the mutation is inherited or has arisen de novo. We have previously reported 28 mutations in individuals with NBCCS, and here we present an additional 4 novel mutations. We have also analyzed relatives of a number of the individuals in whom we have found mutations. In total we have identified 8 individuals who carry a de novo mutation in the PTCH gene. In 5 of these cases, clinical and radiological examination had not unequivocally ruled out a diagnosis in one of the parents. This helps to define the clinical phenotype and suggests that diagnostic criteria in this complex syndrome may require review.
Subject(s)
Basal Cell Nevus Syndrome/genetics , Membrane Proteins/genetics , Mutation , DNA Mutational Analysis , DNA, Neoplasm/analysis , Exons , Humans , Microsatellite Repeats , Patched Receptors , Patched-1 Receptor , Phenotype , Polymorphism, Single-Stranded Conformational , Receptors, Cell SurfaceABSTRACT
The MSSE gene predisposes to the development of multiple invasive but self-healing skin tumours (multiple self-healing squamous epitheliomata, MSSE). MSSE (previously named ESS1) was mapped to chromosome 9q by linkage analysis; haplotype analysis in families then suggested a common founder mutation and indicated that the gene lies in the interval D9S1-D9S29 (9q22-q31). Squamous cell carcinomata also develop as one of the complications of xeroderma pigmentosum, and one of the xeroderma pigmentosum genes (XPA) maps within the MSSE interval. We have investigated the hypothesis that a novel dominant mutation in XPA is responsible for MSSE. We screened the entire coding region, 3' untranslated region (UTR) and 5'UTR of XPA for germline mutations in MSSE families by single-stranded conformation polymorphism analysis and by direct DNA sequencing. No mutations were detected but a novel intragenic polymorphism was identified in the 5'UTR of XPA, in both MSSE-affected and unrelated normal individuals. This XPA polymorphism and nine new polymorphic markers that map in the MSSE region were typed in eleven MSSE families; XPA was excluded as the MSSE gene and the most likely location of MSSE was reduced to the interval between D9S197 and (D9S287, D9S1809). The Patched (PTCH) gene, which is mutated in naevoid basal cell carcinoma syndrome (NBCCS or Gorlin syndrome) lies in this interval and all MSSE families have been shown to share a common haplotype at three novel intragenic PTCH polymorphisms. Although no mutation has been detected in MSSE families, PTCH has not been excluded as the MSSE gene.